- Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
- Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
- Arcus Biosciences Announces New Employment Inducement Grants
- Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
- Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
- Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
- Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
More ▼
Key statistics
On Monday, Arcus Biosciences Inc (RCUS:NYQ) closed at 15.84, 22.32% above the 52 week low of 12.95 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.82 |
---|---|
High | 16.82 |
Low | 15.55 |
Bid | 15.32 |
Offer | 16.66 |
Previous close | 15.07 |
Average volume | 703.17k |
---|---|
Shares outstanding | 90.95m |
Free float | 53.82m |
P/E (TTM) | -- |
Market cap | 1.37bn USD |
EPS (TTM) | -3.10 USD |
Data delayed at least 15 minutes, as of Jun 04 2024 00:00 BST.
More ▼